- Home
- OXSQ vs SAVA Comparison
OXSQ vs SAVA Comparison
Compare OXSQ & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXSQ
- SAVA
- Stock Information
- Founded
- OXSQ 2003
- SAVA 1998
- Country
- OXSQ United States
- SAVA United States
- Employees
- OXSQ N/A
- SAVA N/A
- Industry
- OXSQ Blank Checks
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- OXSQ Finance
- SAVA Health Care
- Exchange
- OXSQ Nasdaq
- SAVA Nasdaq
- Market Cap
- OXSQ 144.4M
- SAVA 157.5M
- IPO Year
- OXSQ N/A
- SAVA N/A
- Fundamental
- Price
- OXSQ $1.92
- SAVA $2.94
- Analyst Decision
- OXSQ
- SAVA Buy
- Analyst Count
- OXSQ 0
- SAVA 2
- Target Price
- OXSQ N/A
- SAVA $5.00
- AVG Volume (30 Days)
- OXSQ 757.9K
- SAVA 1.9M
- Earning Date
- OXSQ 11-04-2025
- SAVA 11-07-2025
- Dividend Yield
- OXSQ 21.99%
- SAVA N/A
- EPS Growth
- OXSQ N/A
- SAVA N/A
- EPS
- OXSQ N/A
- SAVA N/A
- Revenue
- OXSQ $40,142,565.00
- SAVA N/A
- Revenue This Year
- OXSQ N/A
- SAVA N/A
- Revenue Next Year
- OXSQ $0.12
- SAVA N/A
- P/E Ratio
- OXSQ N/A
- SAVA N/A
- Revenue Growth
- OXSQ N/A
- SAVA N/A
- 52 Week Low
- OXSQ $1.56
- SAVA $1.15
- 52 Week High
- OXSQ $2.96
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- OXSQ 56.13
- SAVA 38.68
- Support Level
- OXSQ $1.83
- SAVA $3.62
- Resistance Level
- OXSQ $1.95
- SAVA $3.06
- Average True Range (ATR)
- OXSQ 0.06
- SAVA 0.25
- MACD
- OXSQ 0.02
- SAVA -0.15
- Stochastic Oscillator
- OXSQ 85.42
- SAVA 9.51
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.